Pfizer Inc.

NYSE:PFE   3:59:59 PM EDT
-0.16 (-0.39%)
4:54:51 PM EDT: $41.34 +0.01 (+0.02%)

U.S. FDA Expands Approval Of Pfizer’S LORBRENA For ALK-Positive Metastatic Lung Cancer

Published: 03/04/2021 01:29 GMT
Pfizer Inc. (PFE) - U.S. FDA Expands Approval of Pfizer’s Lorbrena® As First-line Treatment for Alk-positive Metastatic Lung Cancer.
Pfizer - Approval is Based on Crown Trial, Which Showed a 72% Reduction in Risk of Progression Or Death for Treatment With Lorbrena Versus.